Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 125 of 383

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]Technology appraisal guidanceTBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)NICE guideline
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Technology appraisal guidanceTBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]Technology appraisal guidanceTBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Elafibranor for treating primary biliary cholangitis [ID6331]Technology appraisal guidanceTBC
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177Technology appraisal guidanceTBC
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guideline
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Technology appraisal guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]Technology appraisal guidanceTBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Technology appraisal guidanceTBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Technology appraisal guidance
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Technology appraisal guidanceTBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All